Clinical trialUNITERAREApr 3
Lumos Pharma is testing a new drug called LUM-201 in children who don't produce enough growth hormone naturally. This Phase 3 trial is the final stage of testing before the drug might be approved by the FDA. Researchers are actively recruiting children to participate and see if this treatment helps them grow taller.
WHY IT MATTERSThis is now actively recruiting children with growth hormone deficiency — families interested in potentially accessing LUM-201 before FDA approval should check eligibility requirements and contact the trial sites listed on ClinicalTrials.gov.
Clinical trialUNITERAREApr 3
Researchers are testing a new combination treatment for advanced kidney cancer that has spread to other parts of the body. The treatment combines two immunotherapy drugs (nivolumab and ipilimumab) with an experimental live biotherapeutic product called EXL01. This Phase 1 trial is now accepting patients to see if adding EXL01 to the standard immunotherapy improves outcomes.
WHY IT MATTERSThis trial offers metastatic renal cell carcinoma patients access to a novel combination approach that may enhance the effectiveness of existing immunotherapies by incorporating a live biotherapeutic product.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
WHY IT MATTERSThis Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
Clinical trialUNITERAREApr 3
This is a clinical trial testing a blood clotting medicine called Nuwiq in women and girls with hemophilia A who need surgery. Hemophilia A is a rare bleeding disorder where the body doesn't make enough of a protein that helps blood clot. The trial will study how well Nuwiq works and what dose is best for these patients during surgical procedures.
WHY IT MATTERSThis trial is specifically designed for women and girls with hemophilia A undergoing surgery — a population that often receives less research attention than males with the same condition.
Clinical trialUNITERAREApr 3
Triple Hair Inc is recruiting patients for a Phase 3 clinical trial testing a new treatment called TH07 for androgenic alopecia, commonly known as male or female pattern baldness. This is a large-scale study to confirm whether TH07 works better than current treatments. If you have pattern hair loss, you may be eligible to join and help test this potential new therapy.
WHY IT MATTERSThis Phase 3 trial is actively recruiting now, meaning if you have androgenic alopecia, you could potentially enroll and access an investigational treatment while contributing to evidence that could lead to FDA approval.
Clinical trialUNITERAREApr 3
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The therapy uses special immune cells called NK cells that are engineered to recognize and attack cancer cells. This is an early-stage study (Phase 1) that is now accepting patients.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory T-cell lymphoma who have limited alternatives after standard therapies fail, with enrollment beginning in April 2026.
Clinical trialUNITERAREApr 3
Researchers at the University of Wisconsin are testing a new combination of two cancer treatments called Hepzato Kit and Opdualag for patients with melanoma (a type of skin cancer) that has spread to the liver. This is an early-stage study that started in 2026 and is currently looking for patients to participate. The goal is to see if this combination can help people whose cancer has spread to multiple parts of their body.
WHY IT MATTERSThis trial offers patients with metastatic melanoma and liver involvement access to a novel combination therapy at a major academic medical center, potentially providing treatment options for a particularly aggressive cancer presentation.
Clinical trialUNITERAREApr 3
Researchers are testing a new drug called elritercept to see if it works better than a standard treatment (epoetin alfa) for anemia in adults with myelodysplastic syndromes (MDS)—a blood disorder where the bone marrow doesn't make enough healthy blood cells. People in this study have low, very low, or intermediate risk MDS and need regular blood transfusions. The trial is now accepting patients.
WHY IT MATTERSThis Phase 3 trial is actively recruiting adults with MDS who require transfusions, offering access to an investigational treatment that may reduce their dependence on blood transfusions.
Clinical trialUNITERAREApr 3
Researchers at Emory University are looking for pregnant women with sickle cell disease to join a study about blood transfusions. The study will test whether giving blood transfusions during pregnancy can help prevent serious complications for both the mother and baby. This is a Phase 4 trial, which means the treatment has already been tested before and researchers want to learn more about how well it works.
WHY IT MATTERSThis trial is now actively recruiting pregnant women with sickle cell disease — participation could help prevent pregnancy complications like stroke, organ damage, and miscarriage that occur at higher rates in this population.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition that affects how the body processes a protein called phenylalanine — is currently closed and not accepting new applications. The program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have PKU and were relying on this $12,000 annual assistance to afford your special diet or medications, you'll need to find alternative financial support resources immediately.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for myasthenia gravis patients is currently closed. This program normally provides up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026, and patients can check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSMyasthenia gravis patients who struggle to afford medications and treatments need to know this assistance fund is temporarily unavailable and should monitor for reopening or explore alternative financial aid programs.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and is not accepting new applications. This program previously provided up to $12,000 per year to help patients afford treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have hereditary angioedema and rely on financial assistance to afford your medications, you'll need to explore alternative funding sources since this major assistance program is temporarily unavailable.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients interested in applying should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSFabry disease patients who rely on financial assistance to afford expensive enzyme replacement or substrate reduction therapies have lost access to this $12,000 annual benefit, making it harder to maintain continuous treatment.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Pompe disease patients is currently closed and not accepting new applications. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. The fund status changed on April 2, 2026, and patients should check the PAN Foundation website for updates on when it might reopen.
WHY IT MATTERSPompe disease patients who rely on financial assistance to afford enzyme replacement therapy or other treatments now have one fewer funding option available, which could impact their ability to access care.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for ALS (a disease that affects nerve cells controlling muscles) is currently closed and not accepting new applications. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have ALS and were counting on this $12,000 annual assistance from PAN Foundation, you'll need to explore other financial resources immediately, as this fund is no longer available.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for people with primary immunodeficiency is currently closed and not accepting new applications. Primary immunodeficiency is a group of disorders where the immune system doesn't work properly, making it harder to fight infections. When this fund was open, it could help eligible patients pay up to $12,000 per year toward treatment costs.
WHY IT MATTERSPatients with primary immunodeficiency who were relying on this $12,000 annual assistance need to immediately identify alternative funding sources, as this program is no longer accepting applications as of April 2, 2026.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients has closed as of April 2, 2026. This program previously provided up to $12,000 per year to help eligible patients pay for treatment costs. Patients who need financial help with their DMD care should contact PAN Foundation or explore other assistance programs.
WHY IT MATTERSPatients with Duchenne muscular dystrophy who were relying on this $12,000 annual benefit to afford medications or treatments now need to find alternative financial assistance sources immediately.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for idiopathic pulmonary fibrosis (a lung disease where lung tissue becomes scarred and stiff over time) is currently closed and is not accepting new applications. This program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have idiopathic pulmonary fibrosis and need help paying for medications or treatment, you cannot currently apply to this specific PAN Foundation program, so you'll need to explore other financial assistance options.
NewsUNITERAREApr 3
The PAN Foundation's Multiple Sclerosis Fund, which helped patients pay for MS medications and treatments, is currently closed and not accepting new applications. The fund previously offered up to $12,000 per year in financial assistance. The status changed on April 2, 2026, so it may reopen in the future.
WHY IT MATTERSIf you have MS and were relying on this fund to help pay for your medications, you'll need to find alternative financial assistance programs immediately since this specific fund is no longer accepting applications.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance fund for paroxysmal nocturnal hemoglobinuria (PNH) — a rare blood disorder where red blood cells break down too quickly — is currently closed and stopped accepting new applications as of April 2, 2026. This fund previously provided up to $12,000 per year to help patients pay for treatment costs. Patients who need financial help with their PNH medications should check the PAN Foundation website for updates on when the fund might reopen.
WHY IT MATTERSPatients with PNH who were relying on this $12,000 annual benefit to afford their medications now need to find alternative financial assistance programs immediately, as this major funding source is no longer available.